Chromomycin A3
|
WikiDoc Resources for Chromomycin A3 |
|
Articles |
|---|
|
Most recent articles on Chromomycin A3 Most cited articles on Chromomycin A3 |
|
Media |
|
Powerpoint slides on Chromomycin A3 |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Chromomycin A3 at Clinical Trials.gov Trial results on Chromomycin A3 Clinical Trials on Chromomycin A3 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Chromomycin A3 NICE Guidance on Chromomycin A3
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Chromomycin A3 Discussion groups on Chromomycin A3 Patient Handouts on Chromomycin A3 Directions to Hospitals Treating Chromomycin A3 Risk calculators and risk factors for Chromomycin A3
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Chromomycin A3 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Chromomycin A3 is a glycosidic antibiotic produced at the fermentation of a strain of Streptomyces griseus. It is also called toyomycin.
Uses
- Membrane-impermeant G/C-specific fluorescent DNA-binding dye.
- Antibacterial antibiotic.
- Antitumor antibiotic that inhibits RNA synthesis, especially in solid tumors
- Attention: actual medical use is unknown.